Eli Lilly’s Verzenio fails prostate cancer test as possible Novartis showdown nears

Despite reaching new heights in breast cancer, Eli Lilly’s Verzenio has been sent packing in prostate cancer.

Verzenio failed to significantly prolong the time before tumor progression or death when added to Johnson & Johnson’s Zytiga and the corticosteroid prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC), Lilly said Tuesday alongside its fourth-quarter financial results.